首页> 美国卫生研究院文献>Theranostics >Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma
【2h】

Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma

机译:通过PDCD5的Lgr5介导的p53抑制导致肝细胞癌对阿霉素的耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The devastating prognosis of hepatocellular carcinoma (HCC) is partially attributed to chemotherapy resistance. Accumulating evidence suggests that the epithelial-mesenchymal transition (EMT) is a key driving force of carcinoma metastasis and chemoresistance in solid tumors. Leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5), as an EMT inducer, is involved in the potentiation of Wnt signaling in HCC. This study proposes uncovering the roles of Lgr5 in Doxorubicin (Dox) resistance of HCC to improve treatment efficacy for HCC.>Methods: We investigated the expression and significance of Lgr5 in HCC tissue and different cell lines. The effect of Lgr5 in EMT and Dox resistance was analyzed in HCC cells and implanted HCC tumor models. A two-hybrid analysis, using the Lgr5 gene as the bait and a HCC cDNA library, was used to screen targeted proteins that interact with Lgr5. The positive clones were identified by coimmunoprecipitation (Co-IP) and Glutathione-S-transferase (GST) pull-down. The impact of the interaction on Dox resistance was investigated by a series of assays in vitro and in vivo .>Result: We found that Lgr5 was upregulated and positively correlated with poor prognosis in HCC. Additionally, it functioned as a tumor promoter to increase cell migration and induce EMT in HCC cells and increase the resistance to Dox. We identified programmed cell death protein 5 (PDCD5) as a target gene of Lgr5 and we found that PDCD5 was responsible for Lgr5-mediated Dox resistance. Further analysis with Co-IP and GST pull-down assays showed that the N-terminal extracellular domain of Lgr5 could directly bind to PDCD5. Lgr5 induced p53 degradation by blocking the nuclear translocation of PDCD5 and leading to the loss of p53 stabilization. Lgr5 showed a protection against the inhibition of Dox on the growth of tumor subcutaneously injected. Moreover, Lgr5 suppressed Dox-induced apoptosis via the p53 pathway and attenuated the cytotoxicity of Dox to HCC.>Conclusion: Lgr5 induces the EMT and inhibits apoptosis, thus promoting chemoresistance by regulating the PDCD5/p53 signaling axis. Furthermore, Lgr5 may be a potential target gene for overcoming Dox resistance.
机译:肝细胞癌(HCC)的毁灭性预后部分归因于化疗耐药性。越来越多的证据表明,上皮-间质转化(EMT)是实体瘤中癌转移和化学耐药性的关键驱动力。富亮氨酸的含重复序列的G蛋白偶联受体5(Lgr5),作为EMT诱导物,参与了HCC中Wnt信号的增强。本研究旨在揭示Lgr5在肝癌对阿霉素(Dox)的耐药性中的作用,以改善肝癌的治疗效果。>方法:我们研究了Lgr5在肝癌组织和不同细胞系中的表达及其意义。分析了Lgr5在HCC细胞和植入的HCC肿瘤模型中对EMT和Dox抵抗的影响。使用Lgr5基因作为诱饵和HCC cDNA文库进行两次杂交分析,以筛选与Lgr5相互作用的目标蛋白。通过共免疫沉淀(Co-IP)和谷胱甘肽-S-转移酶(GST)下拉鉴定出阳性克隆。通过一系列体外和体内试验研究了相互作用对Dox耐药性的影响。>结果:我们发现Lgr5上调且与肝癌预后不良相关。此外,它还可以作为肿瘤启动子来增加细胞迁移并诱导HCC细胞中的EMT并增加对Dox的抵抗力。我们确定编程的细胞死亡蛋白5(PDCD5)为Lgr5的目标基因,我们发现PDCD5负责Lgr5介导的Dox抵抗。使用Co-IP和GST下拉分析的进一步分析表明,Lgr5的N末端胞外域可以直接结合PDCD5。 Lgr5通过阻止PDCD5的核易位而诱导p53降解,并导致p53稳定性丧失。 Lgr5对皮下注射的肿瘤生长具有抑制Dox抑制作用的保护作用。此外,Lgr5通过p53途径抑制Dox诱导的细胞凋亡,并减弱Dox对HCC的细胞毒性。>结论: Lgr5诱导EMT并抑制细胞凋亡,从而通过调节PDCD5 / p53信号轴来促进化学抗性。此外,Lgr5可能是克服Dox耐药性的潜在靶基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号